Cingulate Inc. (CINGW)
0.04
-0.00 (-10.51%)
At close: Apr 17, 2025, 12:46 PM
0.04
0.00%
After-hours: Apr 17, 2025, 04:00 PM EDT
-10.51% (1D)
| Bid | n/a |
| Market Cap | 168.82K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.24B |
| EPS (ttm) | -1.732 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 3,000 |
| Avg. Volume (20D) | 59,123.132 |
| Open | 0.04 |
| Previous Close | 0.04 |
| Day's Range | 0.04 - 0.04 |
| 52-Week Range | 0.04 - 0.04 |
| Beta | -0.88 |
About CINGW
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CINGW
Website https://www.cingulate.com